Optimizing Chronic Migraine Management Strategies for Managed Care to Reduce Costs and Improve Patient QoL
Optimizing Chronic Migraine Management Strategies for Managed Care to Reduce Costs and Improve Patient QoL
On-Demand Webcast
Faculty
Eric Cannon, PharmD, FAMCP
Chief of Pharmacy
Director of Health and Wellness
SelectHealth
Murray, Utah
Stephen Silberstein, MD, FACP
Professor of Neurology
Jefferson Medical College
Director, Jefferson Headache Center
Thomas Jefferson University
Philadelphia, Pennsylvania
Learning Objectives
After completing this activity, participants should be able to:
- Distinguish between types of migraine headache based on classification and clinical presentation
- Outline the clinical, economic, and quality of life burden of chronic migraine (CM)
- Apply clinical trial and economic evidence for CM prophylaxis options to formulary decision-making
- Describe the impact of patient-centric and treatment-based factors on adherence to CM prophylaxis
Intended Learners
This activity is designed for managed markets physicians and pharmacists.
Activity Overview
This on-demand webcast is available with synchronized slides and audio.
To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
This educational activity is a knowledge-based activity.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for these enduring materials.
Release Date: January 15, 2013
Expiration Date: January 15, 2014
Estimated time to complete: 45 minutes
For questions regarding this educational activity, please call 609-371-1137.
Hardware/Software Requirements
All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
Accreditation
In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME
NACCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This activity is approved for 0.75 contact hour (0.075 CEU) of continuing pharmacy education (UAN 0276-0000-13-024-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Director, Accreditation Services, NACCME, may be made for a second level of review.
Independent Clinical Reviewer: Joseph K. Vaughan, Jr, MD, Assistant Professor, Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, Texas
Planning Committee
The planning committee comprises Eric Cannon, PharmD, FAMCP, William J. Cardarelli, PharmD, Jeffrey B. Gelblum, MD, Stephen Silberstein, MD, FACP, and Joseph K. Vaughan, Jr, MD; and Kristin Ciszeski, Mary Johnson, Mike Kearney, Nick Lombardi, Randy Robbin, and John Savage, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Gelblum: Consultant—Forest Laboratories, Novartis Pharmaceuticals, Pfizer Inc, UCB
Dr. Silberstein: Advisory board—Allergan, Capnia, Iroko Pharmaceuticals, Lilly, MAP, Medtronic, Neuralieve, NINDS, NuPathe, Pfizer, and St. Jude Medical; Consultant—Alderbio, Amgen, Electrocore, Opti-Nose, and Zogenix; Grant/research support—Allergan, Bristol-Myers Squibb, Cumberland, ElectroCore, Lilly, Merck, Merz, Opti-Nose, St. Jude Medical, and Troy Healthcare
Dr. Cannon, Dr. Cardarelli, and Dr. Vaughan disclosed no relevant financial relationships with any commercial interests.
Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.
Mr. Lombardi: Stock shareholder—Inspire Pharmaceuticals, Inc., Vertex Pharmaceuticals; ViroPharma, Inc.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Grant Support
Supported by an educational grant from Allergan, Inc.
